» Articles » PMID: 37996280

Functional Characterization of RYR1 Variants Identified in Malignant Hyperthermia Susceptible Individuals

Overview
Specialty Neurology
Date 2023 Nov 23
PMID 37996280
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant hyperthermia is a pharmacogenetic disorder triggered by halogenated anesthetic agents in genetically predisposed individuals. Approximately 70 % of these individuals carry mutations in RYR1, the gene encoding the ryanodine receptor calcium channel of skeletal muscle. In this study, we performed functional analysis of 5 RYR1 variants identified in members from 8 families who had been diagnosed by the IVCT. Of the 68 individuals enrolled in the study, 43 were diagnosed as MHS, 23 as MHN, and 2 individuals were not tested. Here we demonstrate that the 5 RyR1 variants cause hypersensitivity to RyR1 agonist-mediated calcium release. According to the EMHG scoring matrix these five genetic variants can be classified as follows: c.8638G>A (p.E2880K) and c.11314C>T (p.R3772W) likely pathogenic, c.11416G>A (p.G3806R), c.14627A>G (p.K4876R) and c.14813T>C (p.I4938T), pathogenic (RefSeq NM_000540.3). We propose that the newly functionally characterized RYR1 variants, be included in the panel of variants to be used for the molecular diagnosis of MHS.

Citing Articles

Remimazolam-based total intravenous anesthesia in a patient with a confirmed diagnosis of malignant hyperthermia: a case report.

Kondo H, Mukaida K, Sasai K, Nao Y, Hashimoto K, Miyoshi H JA Clin Rep. 2024; 10(1):26.

PMID: 38647904 PMC: 11035517. DOI: 10.1186/s40981-024-00710-7.